Company profile
Ticker
CGON
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IRS number
371611499
CGON stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
26 Mar 24
8-K
Departure of Directors or Certain Officers
16 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
30 Jan 24
S-8
Registration of securities for employees
26 Jan 24
SEC STAFF
SEC staff action: Order
26 Jan 24
424B4
Prospectus supplement with pricing info
25 Jan 24
EFFECT
Notice of effectiveness
25 Jan 24
S-1MEF
Registration of additional securities for an S-1
24 Jan 24
CERT
Certification of approval for exchange listing
24 Jan 24
S-1/A
IPO registration (amended)
23 Jan 24
Latest ownership filings
SC 13G/A
Decheng Capital Global Life Sciences Fund IV, L.P.
9 Apr 24
4/A
Xiangmin Cui
9 Apr 24
SC 13G
Kissei Pharmaceutical Co., Ltd.
14 Mar 24
SC 13G
TCG Crossover GP I, LLC
9 Feb 24
SC 13G
Decheng Capital Global Life Sciences Fund IV, L.P.
8 Feb 24
SC 13G
Longitude Capital Partners IV, LLC
5 Feb 24
SC 13G
Foresite Capital Fund V, L.P.
5 Feb 24
4
Vijay Kasturi
31 Jan 24
4
Corleen M. Roche
31 Jan 24
4
Hong Fang Song
31 Jan 24
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Common Stock | Buy | Acquire P | Yes | No | 19 | 400,000 | 7.60 mm | 400,000 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Common Stock | Conversion | Acquire C | No | No | 0 | 3,628,198 | 0.00 | 4,558,812 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Series F Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 4,402,320 | 0.00 | 0 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Series E Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 21,547,685 | 0.00 | 0 |
29 Jan 24 | Decheng Capital Global Life Sciences Fund IV | Series C Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 8,644,891 | 0.00 | 0 |
29 Jan 24 | Vijay Kasturi | Common Stock | Buy | Acquire P | No | No | 19 | 1,315 | 24.99 k | 1,315 |
29 Jan 24 | Corleen M. Roche | Common Stock | Buy | Acquire P | No | No | 19 | 2,000 | 38.00 k | 2,000 |
29 Jan 24 | Hong Fang Song | Common Stock | Buy | Acquire P | No | No | 19 | 263,157 | 5.00 mm | 613,928 |
29 Jan 24 | Hong Fang Song | Common Stock | Conversion | Acquire C | Yes | No | 0 | 3,930,176 | 0.00 | 3,930,176 |
29 Jan 24 | Hong Fang Song | Common Stock | Conversion | Acquire C | Yes | No | 0 | 1,011,192 | 0.00 | 1,011,192 |
News
CG Oncology To Unveil Results On Cretostimogene In Combination With Pembrolizumab At ASCO 2024
24 Apr 24
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
4 Apr 24
Goldman Sachs Initiates Coverage On CG Oncology with Neutral Rating, Announces Price Target of $42
20 Feb 24
Morgan Stanley Initiates Coverage On CG Oncology with Overweight Rating, Announces Price Target of $55
20 Feb 24
HC Wainwright & Co. Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $75
14 Feb 24